Indobufen (BioDeep_00000858723)
代谢物信息卡片
Indobufen
化学式: C18H17NO3 (295.1208372)
中文名称: 吲哚布芬
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC(C1=CC=C(C=C1)N2CC3=CC=CC=C3C2=O)C(=O)O
InChI: InChI=1S/C18H17NO3/c1-2-15(18(21)22)12-7-9-14(10-8-12)19-11-13-5-3-4-6-16(13)17(19)20/h3-10,15H,2,11H2,1H3,(H,21,22)
描述信息
B - Blood and blood forming organs > B01 - Antithrombotic agents > B01A - Antithrombotic agents > B01AC - Platelet aggregation inhibitors excl. heparin
D018501 - Antirheumatic Agents > D000894 - Anti-Inflammatory Agents, Non-Steroidal > D016861 - Cyclooxygenase Inhibitors
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
D004791 - Enzyme Inhibitors
同义名列表
1 个代谢物同义名
数据库引用编号
8 个数据库交叉引用编号
- ChEBI: CHEBI:135239
- KEGGdrug: D70894
- KEGGdrug: D07141
- PubChem: 107641
- DrugBank: DB12545
- ChEMBL: CHEMBL1765292
- CAS: 36690-96-7
- CAS: 63610-08-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xin-Yi Gao, Yue-Ming Liu, Dan-Na Zheng, Yi-Wen Li, Hua Li, Xiao-Ling Xiong, Hong-Yu Chen, Hua Wang, Xiao-Yong Yu, Kai Qu, Juan Jin, Bo Lin, Qiang He. Comparison of the prophylactic antithrombotic effect of indobufen and warfarin in patients with nephrotic syndrome: a randomized controlled trial.
Renal failure.
2023 Dec; 45(1):2163505. doi:
10.1080/0886022x.2022.2163505. [PMID: 36636998] - Mingwen Yang, Zekang Ye, Lianlian Mei, Inam Ullah, Chuchu Tan, Guoyu Wang, Qian Gu, Yi Lu, Samee Abdus, Lu Shi, Xiaoxuan Gong, Jianling Bai, John W Eikelboom, Chunjian Li. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
European journal of clinical pharmacology.
2021 Dec; 77(12):1815-1823. doi:
10.1007/s00228-021-03177-y. [PMID: 34331551] - Xiaowei Lou, Juan Jin, Jianguang Gong, Li Zhao, Yiwen Li, Qiang He. Comparison of the Effects of Indobufen and Warfarin in a Rat Model of Adenine-Induced Chronic Kidney Disease.
Medical science monitor : international medical journal of experimental and clinical research.
2019 May; 25(?):3566-3572. doi:
10.12659/msm.915590. [PMID: 31086128] - Jia Liu, Dan Xu, Nian Xia, Kai Hou, Shijie Chen, Yu Wang, Yunman Li. Anticoagulant Activities of Indobufen, an Antiplatelet Drug.
Molecules (Basel, Switzerland).
2018 Jun; 23(6):. doi:
10.3390/molecules23061452. [PMID: 29914049] - Franciszek K Główka, Marta Karaźniewicz. Resolution of indobufen enantiomers by capillary zone electrophoresis. Pharmacokinetic studies of human serum.
Journal of chromatography. A.
2004 Apr; 1032(1-2):219-25. doi:
10.1016/j.chroma.2003.10.056. [PMID: 15065799] - Franciszek K Główka, John Caldwell. Protein binding of indobufen enantiomers: pharmacokinetics of free fraction-studies after single or multiple doses of rac-indobufen.
Chirality.
2002 Oct; 14(9):736-41. doi:
10.1002/chir.10137. [PMID: 12237835] - F K Glówka, D Strzelecka, S Zapalski. Steady-state pharmacokinetics of indobufen enantiomers in patients with obliterative atherosclerosis.
Chirality.
2001 Jun; 13(6):308-12. doi:
10.1002/chir.1036. [PMID: 11370020] - F K Główka. LC procedure with SPE for quantification of indobufen enantiomers: pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis.
2000 Feb; 22(1):93-100. doi:
10.1016/s0731-7085(99)00259-9. [PMID: 10727127] - F K Główka. Stereoselective pharmacokinetics of indobufen from tablets and intramuscular injections in man.
Chirality.
2000 Jan; 12(1):38-42. doi:
10.1002/(sici)1520-636x(2000)12:1<38::aid-chir7>3.0.co;2-o. [PMID: 10602265] - G Davi, P Alessandrini, A Mezzetti, G Minotti, T Bucciarelli, F Costantini, F Cipollone, G B Bon, G Ciabattoni, C Patrono. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Arteriosclerosis, thrombosis, and vascular biology.
1997 Nov; 17(11):3230-5. doi:
10.1161/01.atv.17.11.3230. [PMID: 9409316] - F Cipollone, P Patrignani, A Greco, M R Panara, R Padovano, F Cuccurullo, C Patrono, A G Rebuzzi, G Liuzzo, G Quaranta, A Maseri. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
Circulation.
1997 Aug; 96(4):1109-16. doi:
10.1161/01.cir.96.4.1109. [PMID: 9286937] - A Dmoszyńska, B Sokołowska, A Walter-Croneck, K Przesmycki, A Ledwozyw. Indobufen induced modification of phospholipid composition in diabetic platelets.
Polish journal of pharmacology.
1996 May; 48(3):331-4. doi:
". [PMID: 9112672] - R De Caterina, D Giannessi, W Bernini, G Lazzerini, M Lavezzari, E Stragliotto, G Biagi, S Coccheri. A prostacyclin-sparing effect of indobufen vs. aspirin.
Thrombosis and haemostasis.
1996 Mar; 75(3):510-4. doi:
. [PMID: 8701417] - M Chello, P Mastroroberto, V Celi, F Romano, A R Marchese, A Colonna. Reduction by indobufen of neutrophil activation in peripheral arterial occlusive disease.
Journal of cardiovascular pharmacology.
1996 Mar; 27(3):417-23. doi:
10.1097/00005344-199603000-00015. [PMID: 8907804] - A Dmoszyńska, A Walter-Croneck, A Ledwozyw. Lipid peroxidation products and changes in phospholipid composition induced by indobufen in diabetic platelets.
Thrombosis research.
1995 Sep; 79(5-6):483-90. doi:
10.1016/0049-3848(95)00138-h. [PMID: 7502274] - B Sokołowska, A Dmoszyńska, L Janicka, A Walter-Croneck. [The effect of indobufen on platelet function and dialyzer regeneration in patients on hemodialysis].
Polskie Archiwum Medycyny Wewnetrznej.
1995 Jun; 93(6):475-82. doi:
NULL. [PMID: 7491347] - I Cernak, S Lotina, L Davidović. [The effect of indobufen on patency in femoro-popliteal/crural bypass using artificial grafts].
Vojnosanitetski pregled.
1994 May; 51(3):214-9. doi:
NULL. [PMID: 8560834] - M Palombi, O Bochicchio, M Gargiulo, M Sammarco. [Alternative therapy of deep venous thrombosis in patients at hemorrhagic risk].
Minerva chirurgica.
1994 Mar; 49(3):189-94. doi:
NULL. [PMID: 8028729] - N Grubb, J Caldwell, M Strolin-Benedetti. Excretion balance and urinary metabolites of the S-enantiomer of indobufen in rats and mice.
Biochemical pharmacology.
1993 Oct; 46(8):1507-10. doi:
10.1016/0006-2952(93)90119-h. [PMID: 8240403] - N Grubb, J Caldwell, M Strolin-Benedetti. Excretion balance and urinary metabolism of indobufen in rats and mice.
Biochemical pharmacology.
1993 Aug; 46(4):759-61. doi:
10.1016/0006-2952(93)90565-e. [PMID: 8363649] - H Rdzanek, M Kochmański, R J Zochowski. [Effect of treatment with indobufen on blood viscosity indices and exercise tolerance in patients with coronary disease].
Wiadomosci lekarskie (Warsaw, Poland : 1960).
1993 Apr; 46(7-8):245-9. doi:
NULL. [PMID: 8249409] - M Strolm Benedetti, E Frigerio, V Tamassia, G Noseda, J Caldwell. The dispositional enantioselectivity of indobufen in man.
Biochemical pharmacology.
1992 May; 43(9):2032-4. doi:
10.1016/0006-2952(92)90647-2. [PMID: 1596290] - R De Caterina, R Sicari, A Yan, W Bernini, D Giannessi, G Lazzerini, C Efthymiopoulos, M Strolin-Benedetti. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man.
Thrombosis and haemostasis.
1992 Feb; 67(2):258-63. doi:
10.1055/s-0038-1648422. [PMID: 1621247] - F Fabris, A Steffan, M L Randi, G P Avruscio, I Cordiano, A Girolami. Indobufen versus dipyridamole plus aspirin in the treatment of patients with peripheral atherosclerotic disease.
Journal of medicine.
1992; 23(2):81-92. doi:
NULL. [PMID: 1512524] - M Mares, F Sogaro, M A Scomparin, G Boeri, G Cella. Effect of buflomedil, dipyridamole and indobufene on hemorrheologic and blood coagulation parameters in patients who underwent vascular surgery for severe atherosclerosis.
Journal of medicine.
1991; 22(3):163-9. doi:
NULL. [PMID: 1770324] - C Cerletti, S Manarini, M Colombo, A Tavani. The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (+/-)-indobufen.
The Journal of pharmacy and pharmacology.
1990 Dec; 42(12):885-7. doi:
10.1111/j.2042-7158.1990.tb07049.x. [PMID: 1983157] - P Patrignani, D Volpi, R Ferrario, L Romanzini, M Di Somma, C Patrono. Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood.
European journal of pharmacology.
1990 Nov; 191(1):83-8. doi:
10.1016/0014-2999(90)94098-i. [PMID: 1965501] - M Strolin Benedetti, E Moro, E Frigerio, M G Jannuzzo, R Roncucci, J Caldwell. The dispositional enantioselectivity of indobufen in rat and mouse.
Biochemical pharmacology.
1990 Oct; 40(8):1719-23. doi:
10.1016/0006-2952(90)90347-n. [PMID: 2242009] - C Cimminiello, M Milani, T Uberti, G Arpaia, G Bonfardeci. Effects of ticlopidine and indobufen on platelet aggregation induced by A23187 and adrenaline in the presence of different anticoagulants.
The Journal of international medical research.
1989 Nov; 17(6):514-20. doi:
10.1177/030006058901700603. [PMID: 2516825] - L Mannucci, P Maderna, S Colli, M Lavezzari, C R Sirtori, E Tremoli. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk.
Thrombosis research.
1987 Nov; 48(4):417-26. doi:
10.1016/0049-3848(87)90399-9. [PMID: 3445229] - V Paoletti, T Fattori, F Vaccaro. [Determination of the levels of indobufen in the plasma by reverse-phase HPLC].
Recenti progressi in medicina.
1987 Oct; 78(10):452-4. doi:
NULL. [PMID: 3432724] - G de Gaetano, M R Carriero, C Cerletti, L Mussoni. Low dose aspirin does not prevent fibrinolytic response to venous occlusion.
Biochemical pharmacology.
1986 Sep; 35(18):3147-50. doi:
10.1016/0006-2952(86)90400-4. [PMID: 3755907] - G M Savazzi, A Castiglioni, A Cavatorta, G Garini, M Montanari, A Borghetti. Effect of age on the pharmacokinetics of indobufen.
International journal of clinical pharmacology, therapy, and toxicology.
1986 May; 24(5):265-9. doi:
NULL. [PMID: 3733275] - M C Salter, P Mayor, M J Crow, S M Rajah, A M Davison. Microthrombus formation on hemodialysis membranes: a placebo controlled randomized trail of two doses of Indobufen.
Clinical nephrology.
1985 Jul; 24(1):31-6. doi:
NULL. [PMID: 3893815] - M J Crow, M C Salter, D R Donaldson, S M Rajah. Inhibition of platelet function with indobufen: correlation with plasma drug level.
Thrombosis research.
1985 May; 38(3):303-6. doi:
10.1016/0049-3848(85)90159-8. [PMID: 4024045] - G Buccianti, E Pogliani, R Miradoli, M A Colombi, G Valenti, M Lorenz, E E Polli. Reduction of plasma levels of betathromboglobulin and platelet factor 4 during hemodialysis: a possible role for a short acting inhibitor of platelet aggregation.
Clinical nephrology.
1982 Oct; 18(4):204-8. doi:
NULL. [PMID: 6183040] - E M Pogliani, M Colombi, G Cristoforetti, G Valenti, R Miradoli, G Buccianti. Beta-thromboglobulin and platelet factor 4 plasma levels during haemodialysis: effect of indobufen.
Pharmatherapeutica.
1982; 3(2):127-32. doi:
NULL. [PMID: 6179101] - E Wåhlin-Boll, B Brantmark, A Hanson, A Melander, C Nilsson. High-pressure liquid chromatographic determination of acetylsalicylic acid, salicylic acid, diflunisal, indomethacin, indoprofen and indobufen.
European journal of clinical pharmacology.
1981; 20(5):375-8. doi:
10.1007/bf00615408. [PMID: 7286048] - A Vittoria, F Laghi Pasini, G L Messa, T Di Perri, G Corvi, L M Fuccella. Inhibition of platelet aggregation in man by indobufen (K 3920).
The Journal of international medical research.
1981; 9(1):12-7. doi:
10.1177/030006058100900103. [PMID: 7202826] - H Vinazzer, L M Fuccella. Clinical pharmacology studies with indobufen (K 3920): inhibitor of platelet aggregation.
Journal of clinical pharmacology.
1980 May; 20(5-6 Pt 1):316-25. doi:
10.1177/009127008002000502. [PMID: 7400367] - L M Fuccella, G Corvi, E Moro, E Pogliani, V Tamassia, G Tosolini. Pharmacokinetic, bioavailability and pharmacodynamic study of indobufen (K 3920), an inhibitor of platelet aggregation, after a single dose in man.
European journal of clinical pharmacology.
1979 Jun; 15(5):323-7. doi:
10.1007/bf00558435. [PMID: 456403]